Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ching-Wei Chang

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
JAMA Oncology|September 23, 2018
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 StudyLeisha A Emens, Cristina Cruz, Joseph Paul Eder, et al.
Breast Cancer Research and Treatment|November 19, 2022
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancerAditya Bardia, Ingrid Mayer, Eric Winer, et al.
Nature Communications|March 31, 2026
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER<sup>+</sup> HER2<sup>-</sup> locally-advanced or metastatic breast cancerJackson Liang, Christy Ong, Kareem Heslop, et al.
Liver Cancer|July 21, 2025
Consensus Guideline of Ablation for Metastatic Liver Tumors by Taiwan Academy of Tumor AblationMing Shun Wu, Wei-Yu Kao, Ming-Feng Chiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid TumorsSara M Tolaney, Khanh T Do, Joseph P Eder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast CancerKomal L Jhaveri, Meritxell Bellet, Nicholas C Turner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical TrialCharles N Landen, Luciana Molinero, Habib Hamidi, et al.
Hepatology International|February 24, 2026
Taiwan Academy of Tumor Ablation (TATA) consensus on hepatocellular carcinoma ablationChing-Wei Chang, Ming-Shun Wu, Wei-Yu Kao, et al.
Cancer Immunology Research|May 13, 2022
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast CancerKyung-Min Lee, Chang-Ching Lin, Alberto Servetto, et al.
Clinical and Molecular Hepatology|August 4, 2025
Taiwan Liver Cancer Association Management Consensus Guidelines for Intermediate Stage Hepatocellular CarcinomaI-Cheng Lee, Hung-Wei Wang, Wei Teng, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
JAMA Oncology|September 23, 2018
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 StudyLeisha A Emens, Cristina Cruz, Joseph Paul Eder, et al.
Breast Cancer Research and Treatment|November 19, 2022
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancerAditya Bardia, Ingrid Mayer, Eric Winer, et al.
Nature Communications|March 31, 2026
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER<sup>+</sup> HER2<sup>-</sup> locally-advanced or metastatic breast cancerJackson Liang, Christy Ong, Kareem Heslop, et al.
Liver Cancer|July 21, 2025
Consensus Guideline of Ablation for Metastatic Liver Tumors by Taiwan Academy of Tumor AblationMing Shun Wu, Wei-Yu Kao, Ming-Feng Chiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid TumorsSara M Tolaney, Khanh T Do, Joseph P Eder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast CancerKomal L Jhaveri, Meritxell Bellet, Nicholas C Turner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical TrialCharles N Landen, Luciana Molinero, Habib Hamidi, et al.
Hepatology International|February 24, 2026
Taiwan Academy of Tumor Ablation (TATA) consensus on hepatocellular carcinoma ablationChing-Wei Chang, Ming-Shun Wu, Wei-Yu Kao, et al.
Cancer Immunology Research|May 13, 2022
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast CancerKyung-Min Lee, Chang-Ching Lin, Alberto Servetto, et al.
Clinical and Molecular Hepatology|August 4, 2025
Taiwan Liver Cancer Association Management Consensus Guidelines for Intermediate Stage Hepatocellular CarcinomaI-Cheng Lee, Hung-Wei Wang, Wei Teng, et al.
Pageof 11